Search Results
Search here to find what you are looking for. If you are searching for a Teva product, you may want to try searching in one of our product catalogues or feel free to contact us for assistance.
Showing 9 from 9 results
Toronto, Ontario (February 7, 2024) - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., is proud to announce that it has been named to Forbes list of Canada’s Best Employers 2024. Teva Canada ranked No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers.
Teva Canada announces the Approval of HERZUMA®, a biosimilar to HERCEPTIN® for the treatment of adult patients with Early Breast Cancer, Metastatic Breast Cancer and Metastatic Gastric Cancer.
This is the second Notice of Compliance (NOC) issued for a biosimilar in 2019 that Teva Canada Innovation will add to its portfolio of brands, generics and biosimilars.